Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes

Doxorubicin therapy, effective against many malignancies, is limited by cardiotoxicity.Continuous-infusion doxorubicin, compared with bolus-infusion, reduces early cardiotoxicity in adults.Its effectiveness in reducing late cardiotoxicity in children remains uncertain.WHAT THIS STUDY ADDS: This multicenter randomized trial assessed whether continuous-infusion of doxorubicin in pediatric patients provides long-term cardioprotection or improvement in event-free survival over bolus-infusion in acute lymphoblastic leukemia.Continuous-infusion of doxorubicin provided no cardioprotection or improvement in event-free survival.